



Better Health, Brighter Future

Dear Customer

Takeda Canada Inc. is pleased to share that on July 1, 2020, the amalgamation of Takeda Canada Inc. and Shire Pharma Canada ULC will be complete. Effective this date, Shire Pharma Canada ULC and Takeda Canada Inc. will amalgamate, with the continuing company resulting from the amalgamation to be called Takeda Canada Inc.

We are working closely with wholesalers on changes to ordering requirements as a result of the amalgamation. However, we expect there to be no disruption to your orders with your preferred wholesaler(s). Product registrations will be updated to reflect Takeda Canada Inc. as the new market authorization holder in Canada.

Please update your systems as necessary. To the extent you require any information to update your systems, please let us know.

For adverse event reporting, please use the following link : <https://www.takeda.com/en-ca/who-we-are/contact-us/> to obtain the appropriate contact information.

As a valued partner, I wanted to thank you for your support and collaboration along this journey. Now a fully integrated company, we believe we are better positioned than ever before to bring Better Health and a Brighter Future to patients in Canada.

Best regards,

Takeda Canada Inc.



Ascher Essebag
Business Unit Head, Rare Immunology & HAE



Anand Janack
Business Unit Head, Rare Hematology

Takeda Canada Inc.
Bay Adelaide Centre
22 Adelaide Street West, Suite 3800
Toronto, Ontario M5H 4E3
Tel: +1.647.798.2200 or 1.866.397.4473
Fax: +1.647.798.2490
www.takeda.com/en-ca